Paediatric Committee (PDCO)Draft Agenda for the meeting on 12-15 October 20212.1.8.
2'-O-(2-methoxyethyl) phosphorothioate antisense oligonucleotide targeting CD49dRNA - Orphan - EMEA-002981-PIP01-21 Antisense Therapeutics Limited; Treatment of Duchenne muscular dystrophy
Day 120 opinion
Action: For adoption
“……and they also receive the formal opinion in writing once this has been adopted, which normally happens during the last day of each Committees’ meeting”
For adoption and once this has been adopted are 2 different things?
Ann: Positive feedback received on Paediatric Investigation Plan, page-140
-
- There are more pages in this discussion • 82 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
